These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 6139185)

  • 1. Somatostatin in diabetes.
    Navarro MA; Morató J; Rosel P; Gómez JM
    Clin Chem; 1983 Dec; 29(12):2118-9. PubMed ID: 6139185
    [No Abstract]   [Full Text] [Related]  

  • 2. Response of plasma somatostatin-like immunoreactivity (SLI) to a 75 g oral glucose tolerance test in normal subjects and patients with impaired glucose tolerance.
    Itoh M; Hirooka Y; Nihei N
    Acta Endocrinol (Copenh); 1983 Dec; 104(4):468-74. PubMed ID: 6140806
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impaired somatostatin response to orally administered glucose in type II diabetes entails both somatostatin-28 and -14 and is associated with deranged metabolic control.
    Gutniak M; Grill V; Roovete A; Efendic S
    Acta Endocrinol (Copenh); 1989 Sep; 121(3):322-6. PubMed ID: 2572124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Somatostatin-like activity (SLI) in the blood during metformin treatment of obese patients with diabetes mellitus type 2].
    Lawecki J; Stryjek-Kamińska D; Schusdziarra V
    Pol Arch Med Wewn; 1989 Mar; 81(3):183-8. PubMed ID: 2576469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Increased somatostatin response to glucagon in insulin-dependent diabetes mellitus.
    Kirilov G; Borissova AM; Abadjieva Z; Javorska N
    Acta Physiol Pharmacol Bulg; 1991; 17(1):41-4. PubMed ID: 1687718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Ratio of somatostatin-glucagon secretion in diabetes mellitus].
    Kostiuk EP
    Fiziol Zh (1978); 1985; 31(2):195-201. PubMed ID: 2860024
    [No Abstract]   [Full Text] [Related]  

  • 7. Effect of a 12-hour subcutaneous infusion of somatostatin-14 on blood glucose, insulin and glucagon levels in healthy subjects and insulin dependent diabetics.
    Villaume C; Beck B; Kolopp M; Toussain P; Debry G
    Biomed Pharmacother; 1986; 40(2):61-4. PubMed ID: 2875745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A stimulating effect of glucose on somatostatin release is impaired in noninsulin-dependent diabetes mellitus.
    Grill V; Gutniak M; Roovete A; Efendić S
    J Clin Endocrinol Metab; 1984 Aug; 59(2):293-7. PubMed ID: 6145723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relation between pyloric dysmotility and serum levels of gastrin, somatostatin and vasoactive intestinal polypeptide in patients with non-insulin dependent diabetes mellitus].
    Kostic N ; Ratković M; Novaković R; Secen S
    Med Pregl; 1995; 48(5-6):149-51. PubMed ID: 7565332
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fasting and postprandial concentrations of somatostatin-28 and somatostatin-14 in type II diabetes in men.
    D'Alessio DA; Ensinck JW
    Diabetes; 1990 Oct; 39(10):1198-202. PubMed ID: 1976558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postprandial glycaemic effects of a long-acting somatostatin analogue (octreotide) in non-insulin dependent diabetes mellitus.
    Williams G; Füessl HS; Burrin JM; Chilvers E; Bloom SR
    Horm Metab Res; 1988 Mar; 20(3):168-70. PubMed ID: 2898427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The use of radioimmunoassay in the study of the secretory potential of beta-cells in patients with insulin-independent diabetes mellitus].
    Balabolkin MI; Sharapov AN
    Med Radiol (Mosk); 1984 Nov; 29(11):33-6. PubMed ID: 6390067
    [No Abstract]   [Full Text] [Related]  

  • 13. [Role of a prolonged-action analog of somatostatin SMS 201-995 in the therapy of type 2 diabetes mellitus].
    Candrina R; Giustina G
    Medicina (Firenze); 1988; 8(3):313-5. PubMed ID: 3231042
    [No Abstract]   [Full Text] [Related]  

  • 14. Effects of insulin on fasting and meal-stimulated somatostatin-like immunoreactivity in noninsulin-dependent diabetes mellitus: evidence for more than one mechanism of action.
    Gutniak M; Grill V; Efendić S
    J Clin Endocrinol Metab; 1986 Jan; 62(1):77-83. PubMed ID: 2866196
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma somatostatin-like immunoreactivity and somatostatin-28 levels in obese men.
    Peracchi M; Carola F; Cavagnini F; Benti R; Bareggi B; Baccalaro G; Basilisco G
    J Endocrinol Invest; 1998 Jan; 21(1):20-3. PubMed ID: 9633018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of composition of mixed meals--low- versus high-carbohydrate content--on insulin, glucagon, and somatostatin release in healthy humans and in patients with NIDDM.
    Gutniak M; Grill V; Efendić S
    Diabetes Care; 1986; 9(3):244-9. PubMed ID: 2873976
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of soy polysaccharide on postprandial plasma glucose, insulin, glucagon, pancreatic polypeptide, somatostatin, and triglyceride in obese diabetic patients.
    Tsai AC; Vinik AI; Lasichak A; Lo GS
    Am J Clin Nutr; 1987 Mar; 45(3):596-601. PubMed ID: 2881482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Plasma somatostatin assay and the clinical significance].
    Saito H
    Nihon Rinsho; 1990 Feb; 48 Suppl():151-6. PubMed ID: 1972423
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunoreactive somatostatin levels in plasma of normal and alloxan diabetic dogs.
    Schusdziarra V; Dobbs RE; Harris V; Unger RH
    FEBS Lett; 1977 Sep; 81(1):69-72. PubMed ID: 332526
    [No Abstract]   [Full Text] [Related]  

  • 20. Glucose and insulin suppression of plasma free fatty acids in obese subjects with normal glucose tolerance or mild, newly diagnosed type 2 (non-insulin-dependent) diabetes.
    Zancanaro C; Cigolini M; Bonora E; Moghetti P; Querena M; Muggeo M
    J Endocrinol Invest; 1990 Jan; 13(1):55-9. PubMed ID: 1969430
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.